NCT04451174.

Methods	Trial design: single‐blinded (outcomes assessor) RCT Sample size: 184 Setting: inpatient Language: Spanish, English Number of centres: 1 Type of intervention (treatment/prevention): treatment
Participants	Inclusion criteria ≥ 18 years COVID‐19 confirmed by PCR Oxygen requirements until 35 % by Venturi mask or 5 L/min by nasal cannula Consent form signed Exclusion criteria Previous steroid use ≥ 48 h Pregnancy Chronic respiratory failure Requirements of mechanical ventilation (invasive or non‐invasive) Chronic liver damage Child Pugh B or C Chronic kidney disease stage IV or V Immunosuppressed Participation on other trial
Interventions	Details of intervention Dose: prednisone 40 mg days 1 to 4 then prednisone 20 mg days 5 to 8 Route of administration: IV Treatment details of control group (e.g. dose, route of administration): no intervention Concomitant therapy: no information
Outcomes	Primary outcome Admission to ICU Need for IMV or All‐cause death by day 28 (Time frame: 28 days)
Notes	Recruitment status: terminated (corticosteroid use approval) Prospective completion date: 3 December 2020 Date last update was posted: 20 October 2020 Sponsor/funding: University of Chile